
    
      -  This is a prospective, randomized, double blinded, multicenter study

        -  Patients meeting all the enrollment criteria are screened at enrollment and randomized
           to Group 1 (Pharmacological therapy + Single Chamber ICD) or Group 2 (AVJ Ablation +
           CRT-D)

        -  Screened patients are implanted with a FDA approved SJM ICD/CRT-D with compatible lead
           system

        -  Patients are followed at 1, 3, 6 and 12 months post implant

        -  Total # of centers - 20 centers

        -  Sample size - 180 patients
    
  